Aarti Shah oversees Lilly’s global information technology, information security, advanced analytics and data sciences, and digital health.
Lilly testing third potential treatment for COVID-19
The Indianapolis-based drugmaker said it is launching a global trial for the anti-inflammatory drug baricitinib, which it launched two years ago to treat moderately to severely active rheumatoid arthritis.Read More
Eli Lilly begins human testing on potential COVID-19 treatment
Dr. Daniel Skovronsky, chief scientific officer and president of Lilly Research Laboratories, said Lilly has already started “large-scale manufacturing” of the potential treatment.Read More
Lilly teams with Chinese biotech to develop COVID-19 antibody
The partnership marks at least the fourth program Lilly is pursuing to find treatments for COVID-19, a disease that has claimed more than 249,000 lives worldwide, including more than 68,000 in the U.S.Read More
Lilly bracing for COVID-19-related headwinds this year
The Indianapolis-based drugmaker, which reported quarterly earnings Thursday, warned it could feel the effects of rising unemployment, a decrease in new prescriptions, and downward pricing pressure from government health care systems.Read More
So far, the program has enrolled 275 people with diabetes. Health workers in the neighborhoods have completed more than 2,300 check-ins with them—helping them set up doctors’ visits, coaching them on how to shop for food, and helping them with dozens of related problems, from transportation needs to medical insurance.
One senior administration official with knowledge of the discussions said Trump has no deep affection for Alex Azar but is unlikely to change Health and Human Services secretaries as the coronavirus continues to rage.
Eli Lilly and Co.’s breakthroughs during Wood’s 18-year tenure included biosynthetic insulin and the category-smashing antidepressant Prozac.
Eli Lilly and Co.’s treatment Emgality and Teva Pharmaceutical’s drug Ajovy were approved within months of each other in 2018.
The decision means perhaps tens of thousands of additional people can get tested at Lilly’s drive-thru, including people who work in grocery stores, pharmacies, banks and other places listed by the state as essential.
In a deal that could eventually be worth close to a billion dollars, Eli Lilly and Co. is teaming with a British biopharmaceutical company in one of the hottest areas in medical research.
Increasingly, as the planet warms, pressure is building from environmentalists, investors, consumers and the general public for corporate America to do something about it.
The Indianapolis-based drugmaker said it will combine its capability for quickly developing antibodies with AbCellera’s “rapid pandemic response platform,” with the goal of getting a treatment into clinics for human testing within four months.
Indianapolis-based Lilly, the 12th largest employer in Indiana with 10,600 workers in the state, said it didn’t have a specific timeline for how long the precaution would last.
Indiana firms restrict travel, postpone product intros, distribute hand sanitizer in reaction to coronavirus
A growing number of employers have restricted international travel and are now considering what they might need to do within the U.S.
The Indianapolis-based drugmaker exceeded analyst expectations for both profit and revenue during the most recent quarter.
Eli Lilly and Co. said it considered sites in Indianapolis and Pennsylvania but chose North Carolina for quality of life, cost of operations and geographical diversity.
The Indianapolis drugmaker quietly terminated a collaboration with NextCure Inc. after spending $40 million on an up-front fee and equity investment, and with little to show from the partnership.
Analysts have said that Dermira’s lead pipeline product, lebrikizumab, has the potential to be the best in class among a wave of similar antibodies to treat eczema.
Alimta is Lilly’s third-best-selling drug, with global sales of $2.1 billion last year. The court ruling stops a Canadian competitor from launching a generic version of the drug before its patent expires in 2022.
For the Lilly Endowment, a good year means it’s time to cash in.
Under fire from politicians, patients and health care advocates over the price of insulin, Eli Lilly and Co. announced a campaign Thursday morning to raise awareness of cost-saving options for the drug.
The pharmaceutical giant says it needs additional manufacturing capacity to keep up with demand for current medicines and new drugs expected to emerge from its pipeline.